Answers are grounded in this paper and cite their sources.
This overview highlights toxicity prediction factors in lung cancer patients treated with chemotherapy, suggesting improvements in patient care.
SUMMARY Platinum-based chemotherapy is currently the state-of-the-art first-line cytotoxic treatment of advanced-stage small-cell lung cancers and non-small-cell lung cancers, but at the cost of potentially severe toxicity. As platinum-related adverse events may impede the success of palliative chemotherapy, while negatively affecting the patients’ quality of life, treatment strategies should aim at optimizing the toxicity:benefit ratio. The identification and application of clinical and laboratory biomarkers, including pharamacogenetic tools, for reliably predicting toxicity in this setting would significantly contribute to such a customized approach. This is a comprehensive overview of the toxicity-prediction factors with the most potential, including ethnicity, age, gender, performance status, comorbidity and nutrition, as well as molecular biomarkers, such as germline genetic polymorphisms.
No takes yet. Share an insight, caveat, or question.
Ioannidis et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: